Steven Brugger, President and CEO
Steve Brugger brings over 30 years of experience in the biotech and pharmaceutical industry to Affinivax. He most recently served as the Chief Executive Officer of Visterra, a private biotech company based in Cambridge, Mass. During his tenure at Visterra, Steve led the company in closing a Series A round of financing, advancing its lead antibody program toward IND, and establishing strategic partnerships with both Pfizer and the Bill & Melinda Gates Foundation. Prior to Visterra, Steve was the Chief Operating Officer at Momenta Pharmaceuticals. While at Momenta, Steve held several leadership roles as the company grew from a private start-up to a successful public-traded biotechnology company. Prior to Momenta, Steve held various leadership and management positions at Millennium, Novartis, Ayerst, and Hoechst Pharmaceuticals. Steve received his BA in Biology from Susquehanna University and his MBA from the Rutgers Graduate School of Management.
Kamran Tavangar, PhD, Chief Operating Officer
Kamran Tavangar has over 20 years of experience in pharmaceuticals and vaccines. Prior to joining Affinivax, Dr. Tavangar was Vice President of Strategic Product Development at Visterra. Dr. Tavangar previously served in various operational and strategic positions with Novartis for 19 years. Most recently he was the Global Head of Strategic Planning at Novartis Vaccines and Diagnostics, subsequent to being Head of Strategic Global Marketing at Novartis Vaccines. Previously, Dr. Tavangar was the Business Unit Head for Novartis Oncology in Australia. He also served as VP Finance for Novartis Pharmaceuticals USA, as well as Head of Investor Relations for Novartis Corporation USA. Dr. Tavangar received his AB in Molecular Biology from UC Berkeley, PhD in Physiology from Stanford University, and MBA from MIT’s Sloan School of Management.